- Advertise
- Contact Us
- Editorial
- Editorial Board
- Do Not Sell My Personal Information
- Privacy
- Terms and Conditions
© 2021 MJH Life Sciences™ and Diagnostic Imaging. All rights reserved.
Mallinckrodt to distribute Myoview
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of restricted blood supply to the heart muscle, according to the company.
Mallinckrodt of St. Louis and Medi-Physics of Arlington Heights, IL, will both provide the agent in the U.S. The agreement also includes a five-year extension.
In other Mallinckrodt news, the company has jointly announced with Molecular Biosystems that MBI's FS069 second-generation ultrasound contrast agent has been given the brand name Optison. Regulatory activity by the Food and Drug Administration on that agent has been temporarily halted following a U.S. District Court preliminary injunction on April 21 (SCAN 4/30/97).
Related Content:
